Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jul 9;25(14):7533.
doi: 10.3390/ijms25147533.

Restoring Skeletal Muscle Health through Exercise in Breast Cancer Patients and after Receiving Chemotherapy

Affiliations
Review

Restoring Skeletal Muscle Health through Exercise in Breast Cancer Patients and after Receiving Chemotherapy

Inês Aires et al. Int J Mol Sci. .

Abstract

Breast cancer (BC) stands out as the most commonly type of cancer diagnosed in women worldwide, and chemotherapy, a key component of treatment, exacerbates cancer-induced skeletal muscle wasting, contributing to adverse health outcomes. Notably, the impact of chemotherapy on skeletal muscle seems to surpass that of the cancer itself, with inflammation identified as a common trigger for muscle wasting in both contexts. In skeletal muscle, pro-inflammatory cytokines modulate pathways crucial for the delicate balance between protein synthesis and breakdown, as well as satellite cell activation and myonuclear accretion. Physical exercise consistently emerges as a crucial therapeutic strategy to counteract cancer and chemotherapy-induced muscle wasting, ultimately enhancing patients' quality of life. However, a "one size fits all" approach does not apply to the prescription of exercise for BC patients, with factors such as age, menopause and comorbidities influencing the response to exercise. Hence, tailored exercise regimens, considering factors such as duration, frequency, intensity, and type, are essential to maximize efficacy in mitigating muscle wasting and improving disease outcomes. Despite the well-established anti-inflammatory role of aerobic exercise, resistance exercise proves equally or more beneficial in terms of mass and strength gain, as well as enhancing quality of life. This review comprehensively explores the molecular pathways affected by distinct exercise regimens in the skeletal muscle of cancer patients during chemotherapy, providing critical insights for precise exercise implementation to prevent skeletal muscle wasting.

Keywords: aerobic exercise; mammary tumorigenesis; metabolic remodeling; muscle wasting; physical activity; resistance training.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Bibliometric network analysis of common terms implicated in cancer, chemotherapy, and exercise. Node size is associated with the frequency of the term and the edges signalize co-occurring terms. Different colored lines represent clusters of associated terms. The co-occurrence network visualization map was created using VOSviewer (version 1.6.20).
Figure 2
Figure 2
Overview of the key molecular mechanisms involved in Breast Cancer (BC) and chemotherapy-induced muscle wasting, and the impact of different exercise types on them. The BC effect is represented in brown, chemotherapy in blue, aerobic exercise in green, and resistance exercise in purple. Figure was created with BioRender.com.

Similar articles

Cited by

References

    1. Key T.J., Verkasalo P.K., Banks E. Epidemiology of Breast Cancer. Lancet Oncol. 2001;2:133–140. doi: 10.1016/S1470-2045(00)00254-0. - DOI - PubMed
    1. Pernas S., Tolaney S.M. HER2-Positive Breast Cancer: New Therapeutic Frontiers and Overcoming Resistance. Ther. Adv. Med. Oncol. 2019;11:1758835919833519. doi: 10.1177/1758835919833519. - DOI - PMC - PubMed
    1. Bailleux C., Eberst L., Bachelot T. Treatment Strategies for Breast Cancer Brain Metastases. Br. J. Cancer. 2021;124:142–155. doi: 10.1038/s41416-020-01175-y. - DOI - PMC - PubMed
    1. Anampa J., Makower D., Sparano J.A. Progress in Adjuvant Chemotherapy for Breast Cancer: An Overview. BMC Med. 2015;13:195. doi: 10.1186/s12916-015-0439-8. - DOI - PMC - PubMed
    1. Torti F.M., Bristow M.M., Lum B.L., Carter S.K., Howes A.E., Aston D.A., Brown B.W., Hannigan J.F., Meyers F.J., Mitchell E.P. Cardiotoxicity of Epirubicin and Doxorubicin: Assessment by Endomyocardial Biopsy. Cancer Res. 1986;46:3722–3727. - PubMed

Substances